Cargando…

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Histone deacetylase (HDAC) is one of the most characterized epigenetic modifiers, modulating chromatin structure and gene expression, which plays an important role in cell cycle, differentiation and apoptosis. Dysregulation of HDAC promotes cancer progression, thus inhibitors targeting HDACs have ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yichen, Hong, Jing Han, Ning, Zhiqiang, Pan, Desi, Fu, Xin, Lu, Xianping, Tan, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481063/ https://www.ncbi.nlm.nih.gov/pubmed/36120308 http://dx.doi.org/10.3389/fphar.2022.932914

Ejemplares similares

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022)

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
por: Wu, Yi-Wen, et al.
Publicado: (2018)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer
por: Shen, Xuetong, et al.
Publicado: (2023)

Identification of cuproptosis-related subtypes in lung adenocarcinoma and its potential significance
por: Pan, Shize, et al.
Publicado: (2022)

Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
por: Zhou, You, et al.
Publicado: (2019)

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
por: Yoshimitsu, Makoto, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS
por: Tejido, Clara, et al.
Publicado: (2021)

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
por: Strawn, Jeffrey R., et al.
Publicado: (2021)

Identification of a Subtype-Selective Allosteric Inhibitor of GluN1/GluN3 NMDA Receptors
por: Zeng, Yue, et al.
Publicado: (2022)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019)

A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo
por: Yan, Zheng, et al.
Publicado: (2021)

Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
por: Naik, Rajashri R., et al.
Publicado: (2022)

MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti‐COVID‐19 Therapeutics
por: Teodori, Laura, et al.
Publicado: (2020)

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases
por: Han, Jung Ho, et al.
Publicado: (2023)

Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic‐associated molecular subtypes and genomic mutations
por: Li, Lijuan, et al.
Publicado: (2023)

Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway
por: Zhao, Tingwei, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Potential Role for Combined Subtype-Selective Targeting of M(1) and M(3) Muscarinic Receptors in Gastrointestinal and Liver Diseases
por: Tolaymat, Mazen, et al.
Publicado: (2021)

Cuproptosis-related molecular subtypes direct T cell exhaustion phenotypes and therapeutic strategies for patients with lung adenocarcinoma
por: Zhu, Yi-Pan, et al.
Publicado: (2023)

Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
por: Bai, Litao, et al.
Publicado: (2018)

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
por: Toutah, Krimo, et al.
Publicado: (2021)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
por: Fontana, Anna, et al.
Publicado: (2022)

Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
por: Li, Jianglei, et al.
Publicado: (2022)

Matrine, a potential c-Myc inhibitor, suppresses ribosome biogenesis and nucleotide metabolism in myeloid leukemia
por: Zhong, Wang-Jing, et al.
Publicado: (2022)

Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
por: Wang, Fa-Da, et al.
Publicado: (2022)

Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells
por: Lee, Jane Ying-Chieh, et al.
Publicado: (2016)

Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?
por: Du, Peixin, et al.
Publicado: (2022)

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Zhou, Bingyi, et al.
Publicado: (2021)

Therapeutic Potential of Polyphenols in Cardiac Fibrosis
por: Zhang, Ning, et al.
Publicado: (2018)

Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases
por: Li, Jianglei, et al.
Publicado: (2022)

Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms
por: Li, Mengyuan, et al.
Publicado: (2023)

HDAC4 in ischemic stroke: mechanisms and therapeutic potential
por: Kong, Qingsheng, et al.
Publicado: (2018)

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
por: Zhang, Mu-Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ec3b77e1ftha6d3kfg83caj4s